Approve study plans and interpret results.

4. Accountability

The Head – Manufacturing is accountable for the execution, compliance, and continuous improvement of the procedures defined in this SOP.

5. Procedure

5.1 Selection of Testing Methodology

1. Decide between in vitro and in vivo methods depending on the formulation phase and regulatory requirement.
2. Use in vitro release testing (IVRT) for semi-solid topical gels using Franz diffusion cells or equivalent systems.
3. Use in vitro permeation testing (IVPT) for skin absorption studies.
4. In vivo studies may be required using animal models or human pharmacokinetic (PK) studies.

5.2 Sample Preparation

1. Use fresh, homogeneous gel batches as test samples.
2. Weigh precise quantities of gel based on dose and protocol.
3. Ensure sample integrity by storing at specified temperatures prior to testing.

5.3 In Vitro Release Testing (IVRT)

1. Assemble Franz diffusion cells with synthetic membranes (e.g., cellulose acetate, Strat-M®).
2. Mount the membrane securely between donor and receptor compartments.
3. Fill receptor with buffer (e.g., PBS pH 7.4) maintained at 32°C ± 0.5°C.
4. Apply gel to the donor side and cover to prevent evaporation.
5. Collect receptor samples at regular intervals (e.g., 0.5, 1, 2, 4, 6, 8 hours).
6. Analyze samples using HPLC or suitable analytical method.

5.4 In Vitro Permeation Testing (IVPT)

1. Use dermatomed human skin or validated animal skin models (e.g., porcine skin).
2. Follow similar setup as IVRT but replace membrane with skin tissue.
3. Track API permeation profile over defined intervals.
4. Determine cumulative amount permeated (µg/cm²) and flux (µg/cm²/hr).

5.5 In Vivo Testing (if applicable)

1. Prepare study protocol and obtain ethical clearance.
2. Administer gel on defined body area (e.g., forearm, back) in clinical studies or lab animals.
3. Collect blood/plasma samples at scheduled time points.
4. Analyze drug concentration via LC-MS/MS or validated analytical method.
5. Calculate pharmacokinetic parameters (Cmax, Tmax, AUC).

5.6 Data Analysis and Interpretation

1. Plot release/permeation profiles using validated software (e.g., WinNonlin®, Excel).
2. Compare performance with reference or marketed gel product, if available.
3. Determine bioequivalence, relative bioavailability, and potential for therapeutic equivalence.

6. Abbreviations

• SOP: Standard Operating Procedure
• API: Active Pharmaceutical Ingredient
• IVRT: In Vitro Release Testing
• IVPT: In Vitro Permeation Testing
• PK: Pharmacokinetics
• HPLC: High Performance Liquid Chromatography
• AUC: Area Under Curve

7. Documents

1. Bioavailability Study Protocol – Annexure-1
2. IVRT/IVPT Analytical Reports – Annexure-2
3. Franz Cell Calibration and Usage Log – Annexure-3
4. In Vivo PK Study Summary – Annexure-4
5. Comparison Report with Reference Product – Annexure-5

8. References

• ICH M10 – Bioanalytical Method Validation
• US FDA Guidance on Topical Bioavailability and Bioequivalence
• OECD Guidelines for Skin Absorption

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Analytical Chemist	QA Executive	Head – Manufacturing
Department	Gel Manufacturing	Quality Assurance	Manufacturing

11. Annexures

Annexure-1: Bioavailability Study Protocol

Study Type	Test Product	Reference	Design	Duration

Annexure-2: IVRT/IVPT Analytical Reports

Time Point (hr)	Amount Released (µg/cm²)	Method	Analyst

Annexure-3: Franz Cell Calibration and Usage Log

Equipment ID	Calibration Date	Calibrated By	Remarks

Annexure-4: In Vivo PK Study Summary

Subject ID	Cmax	Tmax	AUC

Annexure-5: Comparison Report with Reference Product

Parameter	Test Gel	Reference Gel	Bioequivalent (Yes/No)

Revision History

Revision Date	Revision No.	Description of Change	Reason	Approved By
17/03/2022	1.0	Initial SOP release	New procedure	QA Manager
09/06/2025	2.0	Added IVPT and In Vivo methods	Regulatory update	QA Head